Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three time points: before vaccination, after the first dose, and after the second dose. Following complete vaccination, both naive and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naive individuals were lower than in previously infected individuals. After the first vaccine dose, one-third of previously infected individuals lacked neutralizing antibodies; this was improved to one-fifth after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals.
Immune memory to Common Cold Coronaviruses (CCCs) influences SARS-CoV-2 infection outcome, and is crucial for pan-corona vaccine development. We performed a longitudinal analysis of pre-pandemic samples collected from 2016-2019, and assessed CCC-specific CD4+ T cell and antibody responses, comparing to other respiratory viruses and ubiquitous pathogens. Notably, CCC responses were detected in most subjects, with comparable frequencies as other common antigens, and were sustained over time. CCC-specific CD4+ T cell responses were associated with low HLA-DR+CD38+ cell quantity and their magnitude did not correlate with yearly changes in CCC infection prevalence. Similarly, CCC-specific spike RBD-specific IgG responses were stable throughout the sampling period. Finally, high CCC-specific CD4+ T cell reactivity, but not antibody titers, was associated with pre-existing SARS-CoV-2 immunity. These results suggest that steady and sustained CCC responses are likely from a stable pool of memory CD4+ T cells, due to repeated earlier exposures and possibly occasional reinfections.